Xcellbio and AmplifyBio have partnered to enhance the development and manufacturing of engineered T-cell receptor (TCR) therapies for solid tumors. The collaboration aims to streamline and improve the process using Xcellbio’s AVATAR Foundry platform.

Key Points

  • The focus is to optimize manufacturing methods and increase the potency of T-cell therapies for solid tumors.
  • Researchers hope to overcome challenges posed by the microenvironment of solid tumors, which hinders T-cell effectiveness.
  • Xcellbio’s AVATAR Foundry platform enables faster manufacturing times and non-viral workflows, potentially reducing costs.
  • The partnership will involve joint research and development, including identifying key manufacturing elements for TCR therapies.
  • The partnership aims to accelerate the development of therapies targeting human papillomavirus-positive (HPV+) tumors.

This collaboration addresses a critical need for more effective therapies against solid tumors. By combining Xcellbio’s platform with AmplifyBio’s expertise, the partnership aims to improve T-cell therapies’ manufacturability, potency, and scalability.

This partnership highlights the importance of collaborations between technology companies and contract development and manufacturing organizations in advancing the field of cell and gene therapy. By leveraging complementary strengths, the partnership aims to expedite the development of innovative therapies for cancer patients.

Source link: http://www.businesswire.com/news/home/20240520549011/en/AmplifyBio-and-Xcell-Biosciences-Announce-Partnership-to-Manufacture-Solid-Tumor-Targeting-TCR-T-Cell-Therapy

Jon Napitupulu
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.